Johanna Mangana

Zurich, ZH 8091, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Melanoma in older patients in Switzerland: A comparison across age groups including patients over the age of 80 years.

Melanoma in older patients in Switzerland: A comparison across age groups including patients over the age of 80 years.

Journal: Cancer epidemiology
Published: January 14, 2026

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.

Journal: Journal for immunotherapy of cancer
Published: December 04, 2025

The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma.

The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma.

Journal: Swiss medical weekly
Published: August 14, 2025

Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer - results from the Tumor Profiler Melanoma project.

Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer - results from the Tumor Profiler Melanoma project.

Journal: NPJ precision oncology
Published: July 21, 2025

Circulating tumor DNA is prognostic of patient outcome and enables therapy monitoring in metastatic uveal melanoma.

Circulating tumor DNA is prognostic of patient outcome and enables therapy monitoring in metastatic uveal melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 18, 2025

Gender differences in melanoma awareness, diagnosis and treatment: Patient-reported data from a multicentre survey in Switzerland.

Gender differences in melanoma awareness, diagnosis and treatment: Patient-reported data from a multicentre survey in Switzerland.

Journal: Skin health and disease
Published: December 03, 2024

Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.

Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 07, 2024

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.

Journal: European journal of cancer (Oxford, England : 1990)
Published: July 02, 2024

Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity.

Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity.

Journal: Frontiers in cardiovascular medicine
Published: March 28, 2024

Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.

Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: August 30, 2023

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.

Journal: Journal for immunotherapy of cancer
Published: February 17, 2023

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.

Journal: Journal for immunotherapy of cancer
Published: June 09, 2022
Showing 1-12 of 27

Last Updated: 09/26/2026